Affymax
Cupertino
About Affymax
Affymax is a biopharmaceutical company committed to developing novel drugs to improve the treatment of serious and often life-threatening conditions. The company's first product candidate, peginesatide (formerly known as Hematide™), has been investigated in Phase 3 trials for the potential treatment of anemia associated with chronic kidney disease (CKD). A New Drug Application (NDA) for peginesatide for the treatment of anemia associated with CKD in adult patients on dialysis is currently being reviewed by the U.S. Food and Drug Administration (FDA).
Company Facts
- Operating status: Closed
- Company type: For Profit
- IPO status: Public
- Employees: 251 – 500
- Estimated revenue: Less than $1M
- Total funding: $173.0M
- Funding stage: IPO
- Last round: Series Unknown (Mar 2009)
- Ticker: otcqb:AFFY
- Website: affymax.com
- Phone: (650) 812-8700
Industries & Categories
Biopharma, Biotechnology, Health Care
Social Profiles
Canonical: https://fsome.com/organization/affymax-1388909 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.